Biomarkers for prostate cancer

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S007100

Reexamination Certificate

active

07807393

ABSTRACT:
The present invention relates to compositions and methods for the detecting, treating, and empirically investigating the prostate. In particular, the present invention provides compositions and methods for using neuroligin biomarkers (e.g., NLGN-4Y) in the diagnosis, treatment, and empirical investigation of prostate disorders (e.g., prostate cancer, benign prostatic hypertrophy).

REFERENCES:
patent: 2002/0168713 (2002-11-01), Curtis
IHOP entry for the NLGN4Y polypeptide, May 27, 2009.
Epstein and Potter, “The pathological interpretation and significance of prostate needle biopsy findings: implications and current controversies” 2001, J. Urol., 166:402.
Etzioni et al., 1999, J. Natl. Cancer Inst., 91:1033.
Gleason, “Classification of prostatic carcinomas” 1966, Cancer Chemother. Rep. 50:125.
Gleason, “Histologic grading of prostate cancer: a perspective” 1992, Hum. Pathol. 23:273.
Jacobsen et al., “Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing” 1995 JAMA 274:1445.
Jamain et al., “Neuroligin 2 is exclusively localized to inhibitory synapses” 2004 Eur J Cell Biol. 83(9):449-56.
Maattanen et al., “European randomized study of prostate cancer screening: first-year results of the Finnish trial” 1999 Br. J. Cancer 79:1210.
Negase et al., “Prediction of the coding sequences of unidentified human genes XI11 the complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro” 1999, DNA Res. 6:63-70.
Schroder et al., “Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer” 1998 J. Natl. Cancer Inst., 90:1817.
Skaletsky et al., “The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes” 2003, Nature 423:825-837.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Biomarkers for prostate cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Biomarkers for prostate cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biomarkers for prostate cancer will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4154071

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.